Register status of hypertension research in special Chinese population_Chinese Journal of Evidence-Based Medicine

Authors：

ZHONG Ming ^1,2 , SU Yanling ¹ , GUO Ru ¹ ,  LIAO Xiaoyang ¹

1. Ward of General Practice Unit, International Medical Center, West China Hospital of Sichuan University, Chengdu 610041, P.R.China;
2. Department of Neurology, The Second People's Hospital of Neijiang, Neijiang 641000, P.R.China;

Corresponding?author：

LIAO Xiaoyang, Email: 625880796@qq.com

Keywords：

Hypertension; Special population; Clinical trial; Clinical trial registration; Chinese Clinical Trial Registry

DOI：

10.7507/1672-2531.201909086

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To analyze the research status and hot spots of hypertension-related clinical trials in special Chinese population registered on the Chinese Clinical Trial Registry (ChiCTR), so as to provide a basis for the development of hypertension-related research in special population in China.Methods The ChiCTR was searched online (up to August 31^st, 2019, no limitation in the status of trial registration), all clinical trials on hypertension in special population were collected, and the general characteristics, researched diseases, research types, intervention measures and main outcomes of the trials were analyzed.Results A total of 64 hypertension-related clinical trials in special population registered in the ChiCTR were included, including 41 (64.1%) trials registered in last 3 years. The registration status of 46 (71.9%) trials was pre-registration. The registered authors were mainly from colleges and universities or medical institutions (n = 61, 95.3%), of which 60.9% were registered in Beijing, Shanghai, Guangdong, Zhejiang, Jiangsu and Hebei. The researched diseases mainly included elderly hypertension and hypertensive stroke, accounting for 50% of the total. Additionally, 37 (57.8%) clinical trials were intervention studies, of which 21 (56.7%) were drug-based intervention studies. Blood pressure, blood glucose, cardiovascular and cerebrovascular events, blood lipid, cranial MRI and Glasgow Coma Scale were the commonly used outcomes, accounting for 58.5% of the total outcomes. Most blood pressure measurements did not indicate the measurement method (n = 22, 64.7%).Conclusions The quantity of hypertension-related clinical trials in special population registered on the ChiCTR is increasing, however, there exists regional imbalance. The drug intervention-related clinical trials of elderly hypertension have become a research hot spot. However, blood pressure measurement method is not indicated in most trials, and some researchers do not register in time. Therefore, it is suggested that researchers should further strengthen the awareness of carrying out high-quality clinical trials.

Citation： ZHONG Ming, SU Yanling, GUO Ru, LIAO Xiaoyang. Register status of hypertension research in special Chinese population. Chinese Journal of Evidence-Based Medicine, 2020, 20(3): 325-329. doi: 10.7507/1672-2531.201909086 Copy

1.	GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016, 388(10053): 1659-1724.
2.	Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2224-2260.
3.	WHO. Causes of death 2008: data sources and methods. Available at: https://www.who.int/healthinfo/global_burden_disease/cod_2008_sources_methods.pdf.
4.	劉力生. 中國高血壓防治指南2010. 中華高血壓雜志, 2011, 19(8): 701-743.
5.	Lackland DT, Woolson RF. Clinical hypertension research tools: the randomized controlled clinical trial. J Clin Hypertens (Greenwich), 2006, 8(6): 427-431.
6.	De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Circulation, 2005, 111(10): 1337-1338.
7.	吳泰相, 李幼平, 劉關鍵, 等. 中國臨床試驗注冊中心及中國循證醫學中心提高我國臨床試驗質量的策略和措施. 中國循證醫學雜志, 2010, 10(11): 1243-1248.
8.	中國高血壓防治指南修訂委員會. 中國高血壓防治指南2010. 中華心血管病雜志, 2011, 39(7): 579-616.
9.	吳泰相, 米娜瓦爾·阿不都, 郝園, 等. 中國臨床試驗注冊10年: 現狀與問題. 中國循證醫學雜志, 2018, 18(6): 522-525.
10.	吳泰相, 李幼平, 劉關鍵, 等. 臨床試驗注冊制度與循證醫學. 中國循證醫學雜志, 2007, 7(4): 239-243.
11.	鄔蘭, 田國祥, 王行環, 等. 臨床試驗的注冊及注冊平臺比較分析. 中國循證心血管醫學雜志, 2017, 9(2): 129-134.
12.	吳泰相, 李幼平, 李靜, 等. 中國臨床試驗注冊和發表機制及實施說明. 中國動脈硬化雜志, 2006, 14(7): 639-640.
13.	蘇艷玲, 全柳柳, 楊梓鈺, 等. 中國臨床試驗注冊中心注冊高血壓臨床試驗的特征分析. 中國循證醫學雜志, 2018, 18(10): 1114-1117.
14.	李曉暉, 詹思延, 李立明. 隨機化臨床試驗結果分析和解釋的幾個問題. 中華醫學雜志, 2000, 80(6): 74-76.
15.	吳泰相, 李幼平, 卞兆祥, 等. 中醫藥臨床隨機對照試驗報告規范(征求意見稿). 中國循證醫學雜志, 2007, 7(8): 601-605.
16.	全國血壓抽樣調查協作組. 中國人群高血壓患病率及其變化趨勢. 高血壓雜志, 1995, 3(S1): 9-15.
17.	李蘇寧, 陳祚, 王增武, 等. 我國老年人高血壓現狀分析. 中華高血壓雜志, 2019, 27(2): 140-148.
18.	Elliott HL, Meredith PA. Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina. J Hum Hypertens, 2011, 25(1): 63-70.
19.	Zarin DA, Tse T, Williams RJ, et al. Trial reporting in ClinicalTrials.gov - the final rule. N Engl J Med, 2016, 375(20): 1998-2004.

1. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016, 388(10053): 1659-1724.
2. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2224-2260.
3. WHO. Causes of death 2008: data sources and methods. Available at: https://www.who.int/healthinfo/global_burden_disease/cod_2008_sources_methods.pdf.
4. 劉力生. 中國高血壓防治指南2010. 中華高血壓雜志, 2011, 19(8): 701-743.
5. Lackland DT, Woolson RF. Clinical hypertension research tools: the randomized controlled clinical trial. J Clin Hypertens (Greenwich), 2006, 8(6): 427-431.
6. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Circulation, 2005, 111(10): 1337-1338.
7. 吳泰相, 李幼平, 劉關鍵, 等. 中國臨床試驗注冊中心及中國循證醫學中心提高我國臨床試驗質量的策略和措施. 中國循證醫學雜志, 2010, 10(11): 1243-1248.
8. 中國高血壓防治指南修訂委員會. 中國高血壓防治指南2010. 中華心血管病雜志, 2011, 39(7): 579-616.
9. 吳泰相, 米娜瓦爾·阿不都, 郝園, 等. 中國臨床試驗注冊10年: 現狀與問題. 中國循證醫學雜志, 2018, 18(6): 522-525.
10. 吳泰相, 李幼平, 劉關鍵, 等. 臨床試驗注冊制度與循證醫學. 中國循證醫學雜志, 2007, 7(4): 239-243.
11. 鄔蘭, 田國祥, 王行環, 等. 臨床試驗的注冊及注冊平臺比較分析. 中國循證心血管醫學雜志, 2017, 9(2): 129-134.
12. 吳泰相, 李幼平, 李靜, 等. 中國臨床試驗注冊和發表機制及實施說明. 中國動脈硬化雜志, 2006, 14(7): 639-640.
13. 蘇艷玲, 全柳柳, 楊梓鈺, 等. 中國臨床試驗注冊中心注冊高血壓臨床試驗的特征分析. 中國循證醫學雜志, 2018, 18(10): 1114-1117.
14. 李曉暉, 詹思延, 李立明. 隨機化臨床試驗結果分析和解釋的幾個問題. 中華醫學雜志, 2000, 80(6): 74-76.
15. 吳泰相, 李幼平, 卞兆祥, 等. 中醫藥臨床隨機對照試驗報告規范(征求意見稿). 中國循證醫學雜志, 2007, 7(8): 601-605.
16. 全國血壓抽樣調查協作組. 中國人群高血壓患病率及其變化趨勢. 高血壓雜志, 1995, 3(S1): 9-15.
17. 李蘇寧, 陳祚, 王增武, 等. 我國老年人高血壓現狀分析. 中華高血壓雜志, 2019, 27(2): 140-148.
18. Elliott HL, Meredith PA. Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina. J Hum Hypertens, 2011, 25(1): 63-70.
19. Zarin DA, Tse T, Williams RJ, et al. Trial reporting in ClinicalTrials.gov - the final rule. N Engl J Med, 2016, 375(20): 1998-2004.

Chinese Journal of Evidence-Based Medicine

Register status of hypertension research in special Chinese population

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content